Delivery Order 75N95021D00024-75N95022F00001
Award Date
9/23/22
Potential Completion Date
9/22/23
Potential Value
$88K
Federal Agency
National Institute on Drug Abuse
Awardee
Murty Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lexington, KY 40509, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Murty Pharmaceuticals, Inc. has been awarded a $90,784 firm fixed price delivery order by the National Institutes of Health's National Institute on Drug Abuse to conduct drug product stability studies from September 13, 2023 through September 12, 2024. The studies will support the NIH/NIDA's ongoing research efforts to address substance abuse and addiction. As the prime contractor, Murty Pharmaceuticals will perform the stability studies at its facility in Lexington, Kentucky. No...
Murty Pharmaceuticals, Inc. was awarded a $145,728 firm fixed price delivery order contract by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA). The contract is not set aside and is part of the NCATS Drug Product Development Studies 2017-2022 indefinite delivery, indefinite quantity (IDIQ) contract vehicle. Under this task order, Murty Pharmaceuticals will provide drug product development, scale up, stability testing,...
The National Institute on Drug Abuse (NIDA) awarded a $7,831,331.48 cost-plus-fixed-fee contract to Murty Pharmaceuticals, Inc., a minority-owned small disadvantaged business, for the development and manufacturing of pharmaceutical products to treat substance abuse disorders. The 5-year contract, which runs from September 18, 2016 to September 17, 2021, includes the production of morphine sulfate pellets and methamphetamine hydrochloride in support of NIDA's efforts to develop new medications...
<p>This is a federal contract award to Murty Pharmaceuticals, Inc. for research and development (R&D) of health services and associated exploratory development. The contract, valued at $100,000.00, was awarded on March 31, 2001 by a U.S. government agency. It is a definitive, firm fixed-price contract with a completion date of March 31, 2001. The place of performance is Lexington, KY. This contract award does not have a set-aside designation.</p>
This federal contract award was issued by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $143,550.00 firm fixed-price delivery order falls under the NIH Bioanalysis Testing Services 2015-2020 contract vehicle, which provides preclinical research services to support drug discovery and development. The contract does not have a set-aside designation. Pharmaron, a minority-owned, for-profit organization...
This federal contract award is for the manufacture of 5.5-kg of cGMP mitragynine, a drug substance, by Curia Global Inc. (doing business as Amri). The award, with a ceiling value of $3,370,313.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the Department of Health and Human Services. This is a delivery order under the CRO Support for NCATS Drug Substance Development and Manufacture indefinite-delivery/indefinite-quantity (IDIQ)...
This is a delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Curia Global Inc. (doing business as Amri), a for-profit manufacturer, under the Drug Manufacturing and Formulation Program (DMFP) indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The $725,724.21 cost-plus-fixed-fee contract has an ultimate completion date of June 30, 2021 and does not have a set-aside designation. Curia, a leading global contract development and manufacturing...
This is a delivery order task order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Curia Global Inc. (doing business as Amri). The task order, valued at $215,934.00, is for the Medicinal Chemistry Support Program for Therapeutic Development (MCSP), which provides medicinal chemistry and drug discovery services to support NIDA's research initiatives. The contract is a firm-fixed-price delivery order...
This federal contract award to Curia Global Inc., doing business as Amri, is a delivery order under the Drug Manufacturing and Formulation Program (DMFP) indefinite-delivery/indefinite-quantity (IDIQ) contract with the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke. The $2,058,963 cost-plus-fixed-fee contract is for chemistry, manufacturing, and controls development services, exploratory chemistry,...
The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $382,010.00 Firm Fixed Price Delivery Order contract to Vitae Enim Vitae Scientific, Inc. (VEV Scientific) on September 27, 2024. The contract is for dosage form reprocessing and stability studies of the FX-5A injection drug product under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Chemistry, Manufacturing and Controls (CMC) and related services to support drug product development. The contract...